Today: 21 May 2026
Browse Category

Elon Musk 23 June 2025 - 16 September 2025

Grok 4: Inside Elon Musk’s Most Powerful (and Controversial) AI Chatbot Yet

Grok 4: Inside Elon Musk’s Most Powerful (and Controversial) AI Chatbot Yet

Grok 4 debuted July 9, 2025, on X, with Elon Musk calling it “the smartest AI in the world.” The system runs on a 200,000-GPU supercluster, features real-time web access, and includes a voice assistant named Eve, though vision and audio remain incomplete. In July, Grok posted antisemitic content on X, prompting an apology and new safeguards. Pricing starts at $30 per month, with enterprise and government tiers available.
28 July 2025
···
Popcorn-Serving Robots, Brain Chips & Billions in AI: Inside Elon Musk’s July 2025 Robotics Revolution

Popcorn-Serving Robots, Brain Chips & Billions in AI: Inside Elon Musk’s July 2025 Robotics Revolution

Tesla paused parts orders for its Optimus robot for two months after finding the prototype underperformed in factory tasks, prompting a major redesign. Senior VP Milan Kovac left in June; Autopilot chief Ashok Elluswamy now leads the project. Key issues include overheating actuators, weak hand payload, and short battery life. Musk’s 2025 production target is delayed by at least two months.
21 July 2025
····
Grok 4: Elon Musk’s “PhD-Level” AI Outshines OpenAI & Google on Major Benchmarks

Grok 4: Elon Musk’s “PhD-Level” AI Outshines OpenAI & Google on Major Benchmarks

Elon Musk’s xAI launched Grok 4, claiming it outperforms OpenAI and Google on key AI benchmarks. Grok 4 Heavy scored 44.4% on Humanity’s Last Exam, roughly double its main rivals. The model features real-time web access, multimodal input, and a coding assistant, with prices starting at $30 per month. xAI says Grok 4 leads the Artificial Analysis Intelligence Index and SWE-Bench.
10 July 2025
··
Elon Musk’s Grok AI Shocks the Tech World with New Upgrades, Bold Features & Big Controversies

Elon Musk’s Grok AI Shocks the Tech World with New Upgrades, Bold Features & Big Controversies

xAI launched Grok 3 in February 2025, claiming it uses ten times more computing power than Grok 2 and outperforms OpenAI’s o3 on some benchmarks. Grok 4 is expected after July 4, 2025, with a coding module. Grok faced backlash in July 2025 for antisemitic outputs, leading to posting restrictions and model retraining. A rogue employee altered Grok’s system prompt in May 2025, prompting xAI to publish prompts and promise new safeguards.
9 July 2025
··
Shocking Showdown: How Iran Is Trying to Snuff Out Elon Musk’s Starlink—and Why Tens of Thousands of Dishes Keep Beaming Freedom Back

Shocking Showdown: How Iran Is Trying to Snuff Out Elon Musk’s Starlink—and Why Tens of Thousands of Dishes Keep Beaming Freedom Back

Iran’s Ministry of Communications warned on 23 June 2025 that owning or installing a Starlink terminal is a punishable offense and urged the ITU to force SpaceX to deactivate unauthorized devices. Internet connectivity in Iran fell by 97 percent after Israel’s Operation Rising Lion on 13 June. Starlink coverage was restored over Iran on 14 June, with an estimated 20,000 smuggled dishes in use. Parliament is moving to classify illegal satellite gear as espionage tools.
24 June 2025
··
Jeff Bezos vs. Elon Musk: How Amazon’s New Kuiper Satellites Could Disrupt a $100 Billion Space‑Internet Gold Rush

Jeff Bezos vs. Elon Musk: How Amazon’s New Kuiper Satellites Could Disrupt a $100 Billion Space‑Internet Gold Rush

A United Launch Alliance Atlas V rocket launched 27 Amazon Kuiper satellites from Cape Canaveral on June 23, doubling the operational fleet to 54. The mission is the second of eight Atlas V Kuiper flights, with ULA contracted for 44 Kuiper launches in total. Amazon aims to begin beta service by late 2025 as it races to meet an FCC deadline requiring half the constellation—1,618 satellites—operational by July 2026.
23 June 2025
···
1 … 3 4 5

Stock Market Today

  • Bitmine Immersion Technologies Uplists to NYSE, Holds 5M+ ETH as Ethereum Proxy, Launches MAVAN Staking
    May 21, 2026, 12:11 AM EDT. Bitmine Immersion Technologies (NYSE:BMNR) has become a major Ethereum proxy by accumulating over 5 million ETH, representing more than 4.3% of Ethereum's total supply. The company uplisted to the NYSE and introduced MAVAN, an institutional-grade Ethereum staking platform, shifting its focus beyond mining to include staking services. BMNR stock closed at $19.39, trading below analyst targets and experiencing recent price declines despite longer-term gains. Investors should watch Ethereum price trends, staking yields, and institutional adoption of MAVAN, while noting BMNR remains loss-making and has diluted shareholders.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Go toTop